Denali Therapeutics Ownership 2024 | Who Owns Denali Therapeutics Now?
Institutional Ownership
69.91%
Insider Ownership
13.61%
Retail Ownership
16.48%
Institutional Holders
161.00
Denali Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | 9.21% | 0.25% | 13,763,596 | -277,632 | -1.98% | 319,590,699 | Jun 30, 2024 |
| BLACKROCK INC. | 8.82% | 0.01% | 13,174,562 | 974,706 | 7.99% | 305,913,328 | Jun 30, 2024 |
| VANGUARD GROUP INC | 7.57% | 0.01% | 11,312,439 | 344,146 | 3.14% | 262,674,833 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.58% | 0.04% | 9,823,767 | 1,553,818 | 18.79% | 228,107,869 | Jun 30, 2024 |
| CAPITAL RESEARCH GLOBAL INVESTORS | 4.77% | 0.04% | 7,126,533 | 1,076,576 | 17.79% | 165,478,096 | Jun 30, 2024 |
| TEMASEK HOLDINGS (PRIVATE) LTD | 3.82% | 0.62% | 5,706,345 | - | - | 132,501,331 | Jun 30, 2024 |
| CRESTLINE MANAGEMENT, LP | 3.19% | 8.60% | 4,760,732 | -450,000 | -8.64% | 110,544,197 | Jun 30, 2024 |
| STATE STREET CORP | 2.97% | 0.00% | 4,434,790 | -1,889,082 | -29.87% | 102,975,824,000 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.50% | 1.11% | 3,731,695 | - | - | 86,649,958 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.00% | 0.01% | 2,982,538 | 222,905 | 8.08% | 69,268,283 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 1.62% | 0.07% | 2,418,833 | 272,454 | 12.69% | 56,165,302 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 1.54% | 0.02% | 2,297,716 | 1,610,477 | 234.34% | 53,352,967 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.51% | 0.01% | 2,255,470 | 661,137 | 41.47% | 52,373,000 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 1.35% | 0.02% | 2,018,534 | 1,880,914 | 1366.74% | 46,870,359 | Jun 30, 2024 |
| CAMBER CAPITAL MANAGEMENT LP | 1.34% | 1.29% | 2,000,000 | 500,000 | 33.33% | 46,440,000 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 1.03% | 0.01% | 1,540,271 | -237,636 | -13.37% | 35,765,097 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.95% | 0.01% | 1,417,472 | 84,522 | 6.34% | 32,913,200 | Jun 30, 2024 |
| CASDIN CAPITAL, LLC | 0.87% | 2.31% | 1,300,000 | - | - | 30,186,000 | Jun 30, 2024 |
| MORGAN STANLEY | 0.82% | 0.00% | 1,223,878 | 295,752 | 31.87% | 28,418,451 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.82% | 0.00% | 1,218,925 | 314,564 | 34.78% | 28,303,439 | Jun 30, 2024 |
Denali Therapeutics's largest institutional shareholder is BAILLIE GIFFORD & CO, holding 9.21% of the company's total share outstanding, currently valued at $319.59M. The top 10 institutional shareholders own together 51.42% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CRESTLINE MANAGEMENT, LP | 3.19% | 8.60% | 4,760,732 | -450,000 | -8.64% | 110,544,197 | Jun 30, 2024 |
| CASDIN CAPITAL, LLC | 0.87% | 2.31% | 1,300,000 | - | - | 30,186,000 | Jun 30, 2024 |
| YIHENG CAPITAL MANAGEMENT, L.P. | 0.77% | 2.15% | 1,150,684 | - | - | 26,718,882 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.17% | 1.71% | 251,010 | 251,010 | 100.00% | 5,828,452 | Jun 30, 2024 |
| CAMBER CAPITAL MANAGEMENT LP | 1.34% | 1.29% | 2,000,000 | 500,000 | 33.33% | 46,440,000 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.50% | 1.11% | 3,731,695 | - | - | 86,649,958 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.33% | 0.87% | 500,000 | 500,000 | 100.00% | 11,610,000 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.22% | 0.72% | 325,000 | 325,000 | 100.00% | 7,546,500 | Jun 30, 2024 |
| CLARIUS GROUP, LLC | 0.27% | 0.67% | 409,995 | 17,777 | 4.53% | 9,520,084 | Jun 30, 2024 |
| TEMASEK HOLDINGS (PRIVATE) LTD | 3.82% | 0.62% | 5,706,345 | - | - | 132,501,331 | Jun 30, 2024 |
| PIER CAPITAL, LLC | 0.11% | 0.57% | 165,486 | -6,845 | -3.97% | 3,842,585 | Jun 30, 2024 |
| HAMILTON LANE ADVISORS LLC | 0.02% | 0.48% | 25,657 | 25,657 | 100.00% | 595,756 | Jun 30, 2024 |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 0.02% | 0.45% | 36,229 | 165 | 0.46% | 841,237 | Jun 30, 2024 |
| CERCANO MANAGEMENT LLC | 0.42% | 0.39% | 625,000 | - | - | 14,512,500 | Jun 30, 2024 |
| PIER 88 INVESTMENT PARTNERS LLC | 0.05% | 0.36% | 69,370 | 29,400 | 73.56% | 1,610,771 | Jun 30, 2024 |
| PDT PARTNERS, LLC | 0.11% | 0.35% | 158,384 | - | - | 3,677,676 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 0.34% | 0.30% | 502,899 | - | - | 11,677,315 | Jun 30, 2024 |
| CONCENTRIC WEALTH MANAGEMENT, LLC | 0.03% | 0.28% | 46,526 | 10,040 | 27.52% | 1,080,334 | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 9.21% | 0.25% | 13,763,596 | -277,632 | -1.98% | 319,590,699 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.03% | 0.17% | 38,000 | 36,000 | 1800.00% | 882,360 | Jun 30, 2024 |
The largest Denali Therapeutics shareholder by % of total assets is CRESTLINE MANAGEMENT, LP. The company owns 4.76M shares of Denali Therapeutics (DNLI), representing 8.60% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALLIANCEBERNSTEIN L.P. | 1.35% | 0.02% | 2,018,534 | 1,880,914 | 1366.74% | 46,870,359 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 1.54% | 0.02% | 2,297,716 | 1,610,477 | 234.34% | 53,352,967 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.58% | 0.04% | 9,823,767 | 1,553,818 | 18.79% | 228,107,869 | Jun 30, 2024 |
| CAPITAL RESEARCH GLOBAL INVESTORS | 4.77% | 0.04% | 7,126,533 | 1,076,576 | 17.79% | 165,478,096 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.70% | 0.06% | 1,053,150 | 1,053,150 | 100.00% | 24,454,138 | Jun 30, 2024 |
| BLACKROCK INC. | 8.82% | 0.01% | 13,174,562 | 974,706 | 7.99% | 305,913,328 | Jun 30, 2024 |
| NORGES BANK | 0.55% | 0.00% | 823,941 | 823,941 | 100.00% | 19,131,910 | Jun 30, 2024 |
| ARTISAN PARTNERS LIMITED PARTNERSHIP | 0.76% | 0.04% | 1,141,517 | 775,685 | 212.03% | 26,506,025 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.51% | 0.01% | 2,255,470 | 661,137 | 41.47% | 52,373,000 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.72% | 0.01% | 1,073,857 | 565,661 | 111.31% | 24,934,960 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.33% | 0.87% | 500,000 | 500,000 | 100.00% | 11,610,000 | Jun 30, 2024 |
| CAMBER CAPITAL MANAGEMENT LP | 1.34% | 1.29% | 2,000,000 | 500,000 | 33.33% | 46,440,000 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.23% | 0.01% | 345,373 | 345,373 | 100.00% | 8,019,561 | Jun 30, 2024 |
| VANGUARD GROUP INC | 7.57% | 0.01% | 11,312,439 | 344,146 | 3.14% | 262,674,833 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.22% | 0.72% | 325,000 | 325,000 | 100.00% | 7,546,500 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.82% | 0.00% | 1,218,925 | 314,564 | 34.78% | 28,303,439 | Jun 30, 2024 |
| MORGAN STANLEY | 0.82% | 0.00% | 1,223,878 | 295,752 | 31.87% | 28,418,451 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 0.49% | 0.10% | 726,499 | 278,621 | 62.21% | 16,868,520 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 1.62% | 0.07% | 2,418,833 | 272,454 | 12.69% | 56,165,302 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.17% | 1.71% | 251,010 | 251,010 | 100.00% | 5,828,452 | Jun 30, 2024 |
As of Jun 30 2024, Denali Therapeutics's largest institutional buyer is ALLIANCEBERNSTEIN L.P.. The company purchased 1.88M stocks of DNLI, valued at $46.87M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 2.97% | 0.00% | 4,434,790 | -1,889,082 | -29.87% | 102,975,824,000 | Jun 30, 2024 |
| FLAGSHIP PIONEERING INC. | - | - | - | -1,364,516 | -100.00% | - | Jun 30, 2024 |
| GILDER GAGNON HOWE & CO LLC | - | - | - | -1,172,785 | -100.00% | - | Jun 30, 2024 |
| FMR LLC | 0.16% | 0.00% | 234,870 | -997,652 | -80.94% | 5,453,690 | Jun 30, 2024 |
| HOLOCENE ADVISORS, LP | 0.04% | 0.01% | 59,042 | -801,906 | -93.14% | 1,370,955 | Jun 30, 2024 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | - | - | - | -498,969 | -100.00% | - | Jun 30, 2024 |
| POLAR CAPITAL HOLDINGS PLC | - | - | - | -452,669 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.04% | 0.01% | 56,554 | -452,011 | -88.88% | 1,313,184 | Jun 30, 2024 |
| CRESTLINE MANAGEMENT, LP | 3.19% | 8.60% | 4,760,732 | -450,000 | -8.64% | 110,544,197 | Jun 30, 2024 |
| ARCH VENTURE MANAGEMENT, LLC | - | - | - | -381,249 | -100.00% | - | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.10% | 0.01% | 151,482 | -283,427 | -65.17% | 3,517,412 | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 9.21% | 0.25% | 13,763,596 | -277,632 | -1.98% | 319,590,699 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.08% | 0.00% | 120,612 | -242,415 | -66.78% | 2,800,611 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 1.03% | 0.01% | 1,540,271 | -237,636 | -13.37% | 35,765,097 | Jun 30, 2024 |
| UBS GROUP AG | 0.09% | 0.00% | 136,223 | -207,656 | -60.39% | 3,163,098 | Jun 30, 2024 |
| TWINBEECH CAPITAL LP | - | - | - | -177,364 | -100.00% | - | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | 0.04% | 0.00% | 58,780 | -152,361 | -72.16% | 1,364,872 | Jun 30, 2024 |
| EDGESTREAM PARTNERS, L.P. | - | - | - | -112,118 | -100.00% | - | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.50% | 0.00% | 742,048 | -109,928 | -12.90% | 17,230,355 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.06% | 0.01% | 94,867 | -96,638 | -50.46% | 2,202,812 | Jun 30, 2024 |
As of Jun 30 2024, Denali Therapeutics's biggest institutional seller is STATE STREET CORP. The company sold -1.89M shares of DNLI, valued at $102.98B.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NORGES BANK | 0.55% | 0.00% | 823,941 | 823,941 | 100.00% | 19,131,910 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.33% | 0.87% | 500,000 | 500,000 | 100.00% | 11,610,000 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.22% | 0.72% | 325,000 | 325,000 | 100.00% | 7,546,500 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.17% | 1.71% | 251,010 | 251,010 | 100.00% | 5,828,452 | Jun 30, 2024 |
| CINCTIVE CAPITAL MANAGEMENT LP | 0.08% | 0.12% | 112,323 | 112,323 | 100.00% | 2,608,140 | Jun 30, 2024 |
| 0.05% | 0.05% | 75,835 | 75,835 | 100.00% | 1,760,871 | Jun 30, 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.05% | 0.00% | 74,704 | 74,704 | 100.00% | 1,733,201 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | 0.01% | 66,875 | 66,875 | 100.00% | 1,552,838 | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | 0.03% | 0.05% | 39,192 | 39,192 | 100.00% | 910,038 | Jun 30, 2024 |
| MAN GROUP PLC | 0.03% | 0.00% | 37,545 | 37,545 | 100.00% | 871,795 | Jun 30, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | 0.02% | 0.01% | 29,357 | 29,357 | 100.00% | 681,669 | Jun 30, 2024 |
| FRED ALGER MANAGEMENT, LLC | 0.02% | 0.00% | 27,014 | 27,014 | 100.00% | 627,265 | Jun 30, 2024 |
| HAMILTON LANE ADVISORS LLC | 0.02% | 0.48% | 25,657 | 25,657 | 100.00% | 595,756 | Jun 30, 2024 |
| FOX RUN MANAGEMENT, L.L.C. | 0.02% | 0.11% | 24,390 | 24,390 | 100.00% | 566,336 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | 0.02% | 0.01% | 24,100 | 24,100 | 100.00% | 559,602 | Jun 30, 2024 |
| FIRST TRUST ADVISORS LP | 0.01% | 0.00% | 19,250 | 19,250 | 100.00% | 446,985 | Jun 30, 2024 |
| LETKO, BROSSEAU & ASSOCIATES INC | 0.01% | 0.01% | 11,350 | 11,350 | 100.00% | 263,547 | Jun 30, 2024 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 0.01% | 0.00% | 10,790 | 10,790 | 100.00% | 249,104 | Jun 30, 2024 |
| MONECO ADVISORS, LLC | 0.01% | 0.03% | 8,700 | 8,700 | 100.00% | 202,014 | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.01% | 0.04% | 8,335 | 8,335 | 100.00% | 193,544 | Jun 30, 2024 |
| SMARTLEAF ASSET MANAGEMENT LLC | 0.00% | 0.00% | 476 | 476 | 100.00% | 10,933 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 117 | 117 | 100.00% | 2,717 | Jun 30, 2024 |
| RONALD BLUE TRUST, INC. | 0.00% | - | 82 | 82 | 100.00% | 1,683 | Jun 30, 2024 |
| VALLEY NATIONAL ADVISERS INC | - | 0.00% | 50 | 50 | 100.00% | 1,000 | Jun 30, 2024 |
| CVA FAMILY OFFICE, LLC | - | 0.00% | 30 | 30 | 100.00% | 697 | Jun 30, 2024 |
| INNEALTA CAPITAL, LLC | - | 0.00% | 30 | 30 | 100.00% | 696 | Jun 30, 2024 |
Denali Therapeutics's largest new institutional shareholder by number of shares is NORGES BANK, purchased 823.94K shares, valued at $19.13M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| FLAGSHIP PIONEERING INC. | - | - | - | -1,364,516 | -100.00% | - | Jun 30, 2024 |
| GILDER GAGNON HOWE & CO LLC | - | - | - | -1,172,785 | -100.00% | - | Jun 30, 2024 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | - | - | - | -498,969 | -100.00% | - | Jun 30, 2024 |
| POLAR CAPITAL HOLDINGS PLC | - | - | - | -452,669 | -100.00% | - | Jun 30, 2024 |
| ARCH VENTURE MANAGEMENT, LLC | - | - | - | -381,249 | -100.00% | - | Jun 30, 2024 |
| TWINBEECH CAPITAL LP | - | - | - | -177,364 | -100.00% | - | Jun 30, 2024 |
| EDGESTREAM PARTNERS, L.P. | - | - | - | -112,118 | -100.00% | - | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -69,314 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -58,847 | -100.00% | - | Jun 30, 2024 |
| BAMCO INC /NY/ | - | - | - | -50,500 | -100.00% | - | Jun 30, 2024 |
| UBS OCONNOR LLC | - | - | - | -50,000 | -100.00% | - | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | - | - | - | -47,000 | -100.00% | - | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -42,288 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -37,749 | -100.00% | - | Jun 30, 2024 |
| LPL FINANCIAL LLC | - | - | - | -34,085 | -100.00% | - | Jun 30, 2024 |
| HARVEST INVESTMENT SERVICES, LLC | - | - | - | -27,978 | -100.00% | - | Jun 30, 2024 |
| SEVEN EIGHT CAPITAL, LP | - | - | - | -20,541 | -100.00% | - | Jun 30, 2024 |
| CAPSTONE INVESTMENT ADVISORS, LLC | - | - | - | -19,741 | -100.00% | - | Jun 30, 2024 |
| ALLIANZ ASSET MANAGEMENT GMBH | - | - | - | -15,400 | -100.00% | - | Jun 30, 2024 |
| SECTORAL ASSET MANAGEMENT INC | - | - | - | -12,081 | -100.00% | - | Jun 30, 2024 |
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -11,001 | -100.00% | - | Jun 30, 2024 |
| MACKENZIE FINANCIAL CORP | - | - | - | -10,560 | -100.00% | - | Jun 30, 2024 |
| PEAK6 INVESTMENTS LLC | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -8,455 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -6,471 | -100.00% | - | Jun 30, 2024 |
| FERNWOOD INVESTMENT MANAGEMENT, LLC | - | - | - | -5,000 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -4,410 | -100.00% | - | Jun 30, 2024 |
| HEADLANDS TECHNOLOGIES LLC | - | - | - | -4,295 | -100.00% | - | Jun 30, 2024 |
| NEW COVENANT TRUST COMPANY, N.A. | - | - | - | -784 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -153 | -100.00% | - | Jun 30, 2024 |
| NAPLES MONEY MANAGEMENT LLC | - | - | - | -45 | -100.00% | - | Jun 30, 2024 |
| FINANCIAL SYNERGIES WEALTH ADVISORS, INC. | - | - | - | -36 | -100.00% | - | Jun 30, 2024 |
Denali Therapeutics's largest sold out institutional shareholder by shares sold is FLAGSHIP PIONEERING INC., sold -1.36M shares, valued at -, as of undefined.
Denali Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| BNY MELLON VARIABLE INVESTMENT FUND | 0.76% | 183,992 | 17,800 | 10.71% | Mar 31, 2024 |
| HARTFORD HLS SERIES FUND II INC | 0.52% | 128,223 | - | - | Dec 31, 2023 |
| Tema ETF Trust | 0.48% | 21,648 | 21,648 | - | Feb 29, 2024 |
| HSBC FUNDS | 0.44% | 14,320 | - | - | Jan 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.39% | 185,311 | 74,980 | 67.96% | Mar 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.39% | 330,708 | 116,210 | 54.18% | Mar 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.28% | 937,262 | 420,077 | 81.22% | Mar 31, 2024 |
| NEW ECONOMY FUND | 0.25% | 1,141,800 | 1,141,800 | - | Feb 29, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.24% | 1,197,891 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.14% | 72,022 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust | 0.12% | 30,843 | 30,843 | - | Mar 31, 2024 |
| T. Rowe Price Diversified Mid-Cap Growth Fund, Inc. | 0.12% | 41,150 | - | - | Mar 31, 2024 |
| VANGUARD SPECIALIZED FUNDS | 0.09% | 5,100,454 | - | - | Jan 31, 2024 |
| ALGER FUNDS | 0.08% | 74,209 | - | - | Jan 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.08% | 159,975 | - | - | Feb 29, 2024 |
| VELA Funds | 0.08% | 25,358 | 5,887 | 30.23% | Dec 31, 2023 |
| BlackRock Health Sciences Trust II | 0.07% | 197,814 | 86,514 | 77.73% | Mar 31, 2024 |
| Humankind Benefit Corp | 0.07% | 1,578 | 270 | 20.64% | Dec 31, 2023 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.07% | 212,100 | -45,700 | -17.73% | Mar 31, 2024 |
| SMALLCAP WORLD FUND INC | 0.06% | 4,269,259 | 1,756,500 | 69.90% | Mar 31, 2024 |
| Voya EQUITY TRUST | 0.05% | 77,684 | 8,227 | 11.84% | Feb 29, 2024 |
| Voya VARIABLE PRODUCTS TRUST | 0.05% | 18,919 | -905 | -4.57% | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.05% | 1,020,500 | -321,000 | -23.93% | Jan 31, 2024 |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 0.05% | 350,000 | - | - | Mar 31, 2024 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.04% | 3,241 | - | - | Sep 30, 2022 |
| WASATCH FUNDS TRUST | 0.04% | 380,297 | 82,184 | 27.57% | Mar 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.04% | 7,680 | 2,294 | 42.59% | Mar 28, 2024 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.04% | 289,638 | -300 | -0.10% | Mar 31, 2024 |
| Federated Hermes MDT Series | 0.04% | 87,096 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.03% | 208,363 | -6,759 | -3.14% | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.03% | 281,664 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.03% | 17,738 | -219 | -1.22% | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.03% | 47,802 | 23,419 | 96.05% | Mar 31, 2024 |
| T. Rowe Price Tax-Efficient Funds, Inc. | 0.03% | 2,500 | - | - | Feb 29, 2024 |
| PRUDENTIAL JENNISON BLEND FUND, INC. | 0.03% | 16,396 | - | - | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND IV | 0.03% | 70,000 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.02% | 9,263,721 | -1,763,939 | -16.00% | Mar 31, 2024 |
| Vericimetry Funds | 0.02% | 1,600 | - | - | Mar 31, 2024 |
| VANGUARD EXPLORER FUND | 0.02% | 200,354 | - | - | Jan 31, 2024 |
| VANGUARD WORLD FUND | 0.02% | 3,910,667 | -137,179 | -3.39% | Feb 29, 2024 |
| Calvert Responsible Index Series, Inc. | 0.02% | 25,982 | - | - | Mar 31, 2024 |
| Northern Lights Variable Trust | 0.02% | 14,684 | - | - | Mar 31, 2024 |
| Harbor ETF Trust | 0.01% | 60,469 | 7,901 | 15.03% | Jan 31, 2024 |
| BARON SELECT FUNDS | 0.01% | 129,200 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 2,697 | - | - | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 34,831 | 558 | 1.63% | Feb 29, 2024 |
| FIDELITY CONTRAFUND | 0.01% | 680,100 | 608,172 | 845.53% | Mar 31, 2024 |
| BNY Mellon Strategic Funds, Inc. | 0.01% | 22,761 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.01% | 394,507 | 27,168 | 7.40% | Jan 31, 2024 |
| VALUED ADVISERS TRUST | 0.01% | 8,780 | - | - | Jan 31, 2024 |
| ALPS ETF Trust | 0.01% | 105,734 | 8,662 | 8.92% | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.01% | 98,482 | 80,248 | 440.10% | Mar 31, 2024 |
| JNL VARIABLE FUND LLC | 0.01% | 43,646 | -5,376 | -10.97% | Mar 31, 2020 |
| AMERICAN CENTURY QUANTITATIVE EQUITY FUNDS, INC. | 0.01% | 15,391 | - | - | Mar 31, 2024 |
| Nushares ETF Trust | 0.01% | 47,340 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.01% | 1,140,343 | -5,024 | -0.44% | Feb 29, 2024 |
| FORUM FUNDS | 0.00% | 11,445 | - | - | Jan 31, 2024 |
| Bernstein Fund Inc | 0.00% | 41,960 | - | - | Mar 31, 2024 |
| LORD ABBETT SECURITIES TRUST | 0.00% | 22,119 | - | - | Jan 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 12,230 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.00% | 16,132 | - | - | Jan 31, 2024 |
| John Hancock Exchange-Traded Fund Trust | 0.00% | 22,543 | - | - | Jan 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 1,791 | -145 | -7.49% | Apr 30, 2021 |
| FIDELITY SELECT PORTFOLIOS | 0.00% | 200,069 | -88,900 | -30.76% | Feb 29, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 18,724 | - | - | Aug 31, 2023 |
| Fidelity Central Investment Portfolios LLC | 0.00% | 140,000 | - | - | Feb 29, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 112,132 | 112,132 | - | Mar 31, 2024 |
| BAILLIE GIFFORD FUNDS | 0.00% | 27,080 | -3,905 | -12.60% | Mar 28, 2024 |
| ETFis Series Trust I | 0.00% | 3,540 | 495 | 16.26% | Jan 31, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.00% | 10,400 | - | - | Mar 31, 2024 |
| BNY MELLON FUNDS TRUST | 0.00% | 158,149 | 158,149 | - | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 63,945 | -5,016 | -7.27% | Mar 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 309,131 | 129,022 | 71.64% | Jan 31, 2024 |
| ProFunds | 0.00% | 23,007 | 3,965 | 20.82% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.00% | 37,500 | - | - | Mar 31, 2024 |
| CARILLON SERIES TRUST | 0.00% | 91,027 | - | - | Mar 31, 2024 |
| PFM Multi-Manager Series Trust | 0.00% | 1,300 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 6,528 | - | - | Mar 31, 2024 |
| AMG FUNDS III | 0.00% | 7,155 | - | - | Mar 28, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 15,561 | -1,280 | -7.60% | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 38,996 | -8,301 | -17.55% | Mar 31, 2024 |
| AMG Funds IV | 0.00% | 3,561 | - | - | Jan 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 5,596 | -244 | -4.18% | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 653,477 | 26,552 | 4.24% | Feb 29, 2024 |
| Federated Hermes Adviser Series | 0.00% | 6,654 | - | - | Mar 31, 2024 |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0.00% | 41,100 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 22,562 | 670 | 3.06% | Mar 31, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 19,493 | - | - | Mar 31, 2024 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 101,689 | -11,612 | -10.25% | Mar 31, 2024 |
| OPTIMUM FUND TRUST | 0.00% | 40,750 | - | - | Mar 28, 2024 |
| TIMOTHY PLAN | 0.00% | 4,295 | - | - | Mar 31, 2024 |
| STEWARD FUNDS, INC. | 0.00% | 2,180 | - | - | Jan 31, 2024 |
| SSGA FUNDS | 0.00% | 377 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 377,917 | 15,263 | 4.21% | Jan 31, 2024 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 7,262 | 7,262 | - | Mar 28, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,799 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 41,636 | -600 | -1.42% | Mar 31, 2024 |
| NEW COVENANT FUNDS | 0.00% | 2,631 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 608,006 | 142,506 | 30.61% | Jan 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 10,307 | -5,317 | -34.03% | Mar 31, 2024 |
Denali Therapeutics's largest mutual fund holder by % of total assets is "BNY MELLON VARIABLE INVESTMENT FUND", owning 183.99K shares, compromising 0.76% of its total assets.
Denali Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 161 | -23.70% |
| 31 Mar, 24 | 211 | -3.21% |
| 31 Dec, 23 | 218 | 10.66% |
| 30 Sep, 23 | 197 | -1.99% |
| 30 Jun, 23 | 201 | -0.50% |
| 31 Mar, 23 | 202 | 1.51% |
| 31 Dec, 22 | 199 | 0.51% |
| 30 Sep, 22 | 198 | 9.39% |
| 30 Jun, 22 | 181 | -0.55% |
| 31 Mar, 22 | 182 | -13.74% |
| 31 Dec, 21 | 211 | -1.86% |
| 30 Sep, 21 | 215 | - |
| 30 Jun, 21 | 215 | -4.44% |
| 31 Mar, 21 | 225 | 5.63% |
| 31 Dec, 20 | 213 | 21.71% |
| 30 Sep, 20 | 175 | 20.69% |
| 30 Jun, 20 | 145 | 10.69% |
| 31 Mar, 20 | 131 | 19.09% |
| 31 Dec, 19 | 110 | -5.98% |
| 30 Sep, 19 | 117 | 1.74% |
| 30 Jun, 19 | 115 | 1.77% |
| 31 Mar, 19 | 113 | 26.97% |
| 31 Dec, 18 | 89 | 14.10% |
| 30 Sep, 18 | 78 | 14.71% |
| 30 Jun, 18 | 68 | 17.24% |
| 31 Mar, 18 | 58 | 28.89% |
| 31 Dec, 17 | 45 | - |
As of 30 Jun 24, 161 institutions are holding Denali Therapeutics's shares, representing a decrease of -23.70% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 104,451,874 | -10.55% |
| 31 Mar, 24 | 116,766,406 | 5.46% |
| 31 Dec, 23 | 110,718,414 | 2.75% |
| 30 Sep, 23 | 107,756,975 | 0.01% |
| 30 Jun, 23 | 107,751,191 | -0.05% |
| 31 Mar, 23 | 107,809,163 | 1.95% |
| 31 Dec, 22 | 105,745,994 | 14.54% |
| 30 Sep, 22 | 92,318,896 | -0.29% |
| 30 Jun, 22 | 92,583,076 | 6.83% |
| 31 Mar, 22 | 86,663,275 | 1.71% |
| 31 Dec, 21 | 85,209,252 | 0.34% |
| 30 Sep, 21 | 84,921,832 | 5.36% |
| 30 Jun, 21 | 80,603,244 | 0.18% |
| 31 Mar, 21 | 80,460,650 | -9.20% |
| 31 Dec, 20 | 88,608,218 | 7.25% |
| 30 Sep, 20 | 82,621,520 | -0.01% |
| 30 Jun, 20 | 82,626,960 | 2.86% |
| 31 Mar, 20 | 80,326,685 | 13.59% |
| 31 Dec, 19 | 70,718,121 | -0.84% |
| 30 Sep, 19 | 71,316,610 | -0.14% |
| 30 Jun, 19 | 71,413,065 | 3.47% |
| 31 Mar, 19 | 69,021,005 | 1.36% |
| 31 Dec, 18 | 68,095,251 | 1.68% |
| 30 Sep, 18 | 66,971,885 | 7.66% |
| 30 Jun, 18 | 62,206,524 | 1.84% |
| 31 Mar, 18 | 61,082,898 | 5.05% |
| 31 Dec, 17 | 58,144,610 | - |
Denali Therapeutics (DNLI) has 104.45M shares outstanding as of 30 Jun 24, down -10.55% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 69.91% | 0.97% |
| 31 Mar, 24 | 85.00% | 1.31% |
| 31 Dec, 23 | 80.44% | 1.30% |
| 30 Sep, 23 | 78.63% | 1.26% |
| 30 Jun, 23 | 78.92% | 1.27% |
| 31 Mar, 23 | 78.97% | 1.25% |
| 31 Dec, 22 | 79.58% | 1.42% |
| 30 Sep, 22 | 74.77% | 1.32% |
| 30 Jun, 22 | 75.27% | 1.51% |
| 31 Mar, 22 | 70.65% | 1.45% |
| 31 Dec, 21 | 69.75% | 1.43% |
| 30 Sep, 21 | 69.76% | 1.58% |
| 30 Jun, 21 | 66.45% | 1.50% |
| 31 Mar, 21 | 66.56% | 1.22% |
| 31 Dec, 20 | 73.74% | 1.25% |
| 30 Sep, 20 | 76.86% | 1.26% |
| 30 Jun, 20 | 78.16% | 1.27% |
| 31 Mar, 20 | 78.43% | 1.43% |
| 31 Dec, 19 | 73.97% | 1.34% |
| 30 Sep, 19 | 74.40% | 1.33% |
| 30 Jun, 19 | 74.78% | 1.42% |
| 31 Mar, 19 | 72.67% | 1.39% |
| 31 Dec, 18 | 72.21% | 1.41% |
| 30 Sep, 18 | 71.50% | 1.59% |
| 30 Jun, 18 | 66.96% | 1.44% |
| 31 Mar, 18 | 68.20% | 1.62% |
| 31 Dec, 17 | 64.92% | - |
As of 30 Jun 24, Denali Therapeutics is held by 69.91% institutional shareholders, representing a 0.97% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 92 | -16.36% |
| 31 Mar, 24 | 110 | 3.77% |
| 31 Dec, 23 | 106 | -0.93% |
| 30 Sep, 23 | 107 | -2.73% |
| 30 Jun, 23 | 110 | -3.51% |
| 31 Mar, 23 | 114 | 2.70% |
| 31 Dec, 22 | 111 | 0.91% |
| 30 Sep, 22 | 110 | 19.57% |
| 30 Jun, 22 | 92 | 10.84% |
| 31 Mar, 22 | 83 | -22.43% |
| 31 Dec, 21 | 107 | -6.96% |
| 30 Sep, 21 | 115 | 0.88% |
| 30 Jun, 21 | 114 | -4.20% |
| 31 Mar, 21 | 119 | -2.46% |
| 31 Dec, 20 | 122 | 25.77% |
| 30 Sep, 20 | 97 | 12.79% |
| 30 Jun, 20 | 86 | -2.27% |
| 31 Mar, 20 | 88 | 95.56% |
| 31 Dec, 19 | 45 | -15.09% |
| 30 Sep, 19 | 53 | -17.19% |
| 30 Jun, 19 | 64 | -4.48% |
| 31 Mar, 19 | 67 | 17.54% |
| 31 Dec, 18 | 57 | - |
| 30 Sep, 18 | 57 | 21.28% |
| 30 Jun, 18 | 47 | 11.90% |
| 31 Mar, 18 | 42 | -6.67% |
| 31 Dec, 17 | 45 | - |
92 institutional shareholders have increased their position in DNLI stock as of 30 Jun 24 compared to 110 in the previous quarter (a -16.36% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 48 | -29.41% |
| 31 Mar, 24 | 68 | -2.86% |
| 31 Dec, 23 | 70 | 22.81% |
| 30 Sep, 23 | 57 | 7.55% |
| 30 Jun, 23 | 53 | 3.92% |
| 31 Mar, 23 | 51 | -1.92% |
| 31 Dec, 22 | 52 | -3.70% |
| 30 Sep, 22 | 54 | 1.89% |
| 30 Jun, 22 | 53 | -15.87% |
| 31 Mar, 22 | 63 | -1.56% |
| 31 Dec, 21 | 64 | - |
| 30 Sep, 21 | 64 | 4.92% |
| 30 Jun, 21 | 61 | -12.86% |
| 31 Mar, 21 | 70 | 4.48% |
| 31 Dec, 20 | 67 | 34.00% |
| 30 Sep, 20 | 50 | 47.06% |
| 30 Jun, 20 | 34 | 54.55% |
| 31 Mar, 20 | 22 | -42.11% |
| 31 Dec, 19 | 38 | 52.00% |
| 30 Sep, 19 | 25 | 4.17% |
| 30 Jun, 19 | 24 | -7.69% |
| 31 Mar, 19 | 26 | 23.81% |
| 31 Dec, 18 | 21 | 90.91% |
| 30 Sep, 18 | 11 | -15.38% |
| 30 Jun, 18 | 13 | 62.50% |
| 31 Mar, 18 | 8 | - |
| 31 Dec, 17 | - | - |
48 institutional shareholders have reduced their position in DNLI stock as of 30 Jun 24 compared to 68 in the previous quarter (a -29.41% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 161 | -23.70% | 104,451,874 | -10.55% | 69.91% | 0.97% | 92 | -16.36% | 48 | -29.41% |
| 31 Mar, 24 | 211 | -3.21% | 116,766,406 | 5.46% | 85.00% | 1.31% | 110 | 3.77% | 68 | -2.86% |
| 31 Dec, 23 | 218 | 10.66% | 110,718,414 | 2.75% | 80.44% | 1.30% | 106 | -0.93% | 70 | 22.81% |
| 30 Sep, 23 | 197 | -1.99% | 107,756,975 | 0.01% | 78.63% | 1.26% | 107 | -2.73% | 57 | 7.55% |
| 30 Jun, 23 | 201 | -0.50% | 107,751,191 | -0.05% | 78.92% | 1.27% | 110 | -3.51% | 53 | 3.92% |
| 31 Mar, 23 | 202 | 1.51% | 107,809,163 | 1.95% | 78.97% | 1.25% | 114 | 2.70% | 51 | -1.92% |
| 31 Dec, 22 | 199 | 0.51% | 105,745,994 | 14.54% | 79.58% | 1.42% | 111 | 0.91% | 52 | -3.70% |
| 30 Sep, 22 | 198 | 9.39% | 92,318,896 | -0.29% | 74.77% | 1.32% | 110 | 19.57% | 54 | 1.89% |
| 30 Jun, 22 | 181 | -0.55% | 92,583,076 | 6.83% | 75.27% | 1.51% | 92 | 10.84% | 53 | -15.87% |
| 31 Mar, 22 | 182 | -13.74% | 86,663,275 | 1.71% | 70.65% | 1.45% | 83 | -22.43% | 63 | -1.56% |
| 31 Dec, 21 | 211 | -1.86% | 85,209,252 | 0.34% | 69.75% | 1.43% | 107 | -6.96% | 64 | - |
| 30 Sep, 21 | 215 | - | 84,921,832 | 5.36% | 69.76% | 1.58% | 115 | 0.88% | 64 | 4.92% |
| 30 Jun, 21 | 215 | -4.44% | 80,603,244 | 0.18% | 66.45% | 1.50% | 114 | -4.20% | 61 | -12.86% |
| 31 Mar, 21 | 225 | 5.63% | 80,460,650 | -9.20% | 66.56% | 1.22% | 119 | -2.46% | 70 | 4.48% |
| 31 Dec, 20 | 213 | 21.71% | 88,608,218 | 7.25% | 73.74% | 1.25% | 122 | 25.77% | 67 | 34.00% |
| 30 Sep, 20 | 175 | 20.69% | 82,621,520 | -0.01% | 76.86% | 1.26% | 97 | 12.79% | 50 | 47.06% |
| 30 Jun, 20 | 145 | 10.69% | 82,626,960 | 2.86% | 78.16% | 1.27% | 86 | -2.27% | 34 | 54.55% |
| 31 Mar, 20 | 131 | 19.09% | 80,326,685 | 13.59% | 78.43% | 1.43% | 88 | 95.56% | 22 | -42.11% |
| 31 Dec, 19 | 110 | -5.98% | 70,718,121 | -0.84% | 73.97% | 1.34% | 45 | -15.09% | 38 | 52.00% |
| 30 Sep, 19 | 117 | 1.74% | 71,316,610 | -0.14% | 74.40% | 1.33% | 53 | -17.19% | 25 | 4.17% |
| 30 Jun, 19 | 115 | 1.77% | 71,413,065 | 3.47% | 74.78% | 1.42% | 64 | -4.48% | 24 | -7.69% |
| 31 Mar, 19 | 113 | 26.97% | 69,021,005 | 1.36% | 72.67% | 1.39% | 67 | 17.54% | 26 | 23.81% |
| 31 Dec, 18 | 89 | 14.10% | 68,095,251 | 1.68% | 72.21% | 1.41% | 57 | - | 21 | 90.91% |
| 30 Sep, 18 | 78 | 14.71% | 66,971,885 | 7.66% | 71.50% | 1.59% | 57 | 21.28% | 11 | -15.38% |
| 30 Jun, 18 | 68 | 17.24% | 62,206,524 | 1.84% | 66.96% | 1.44% | 47 | 11.90% | 13 | 62.50% |
| 31 Mar, 18 | 58 | 28.89% | 61,082,898 | 5.05% | 68.20% | 1.62% | 42 | -6.67% | 8 | - |
| 31 Dec, 17 | 45 | - | 58,144,610 | - | 64.92% | - | 45 | - | - | - |
Denali Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Denali Therapeutics's stock was made by Schuth Alexander O. on Aug 15 2024, selling 2,272 shares at $22.89 per share (valued at $52.01K).
Denali Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 6 | - |
| Q2 2024 | 18 | 5 | 360.00% |
| Q1 2024 | 7 | 17 | 41.18% |
| Q4 2023 | - | 3 | - |
| Q3 2023 | 2 | 19 | 10.53% |
| Q2 2023 | 26 | 14 | 185.71% |
| Q1 2023 | 10 | 28 | 35.71% |
| Q4 2022 | 1 | 4 | 25.00% |
| Q3 2022 | 3 | 12 | 25.00% |
| Q2 2022 | 17 | 3 | 566.67% |
| Q1 2022 | 13 | 17 | 76.47% |
| Q4 2021 | 1 | 31 | 3.23% |
| Q3 2021 | 1 | 33 | 3.03% |
| Q2 2021 | 26 | 45 | 57.78% |
| Q1 2021 | 16 | 112 | 14.29% |
| Q4 2020 | 2 | 15 | 13.33% |
| Q3 2020 | 8 | 9 | 88.89% |
| Q2 2020 | 16 | 15 | 106.67% |
| Q1 2020 | 13 | 10 | 130.00% |
| Q4 2019 | 3 | 17 | 17.65% |
0 total buy trades, and 6 total sell trades (buy/sell ratio of 0.00%) were made by Denali Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 6 | - |
| Q2 2024 | - | 5 | - |
| Q1 2024 | - | 15 | - |
| Q4 2023 | - | 3 | - |
| Q3 2023 | - | 17 | - |
| Q2 2023 | - | 8 | - |
| Q1 2023 | - | 24 | - |
| Q4 2022 | - | 3 | - |
| Q3 2022 | - | 10 | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | 15 | - |
| Q4 2021 | - | 30 | - |
| Q3 2021 | - | 32 | - |
| Q2 2021 | - | 35 | - |
| Q1 2021 | - | 105 | - |
| Q4 2020 | - | 11 | - |
| Q3 2020 | - | 2 | - |
| Q2 2020 | - | 14 | - |
| Q1 2020 | - | 5 | - |
| Q4 2019 | - | 14 | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 6 open market sell trades of Denali Therapeutics's stocks.
Denali Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| FDMT | 4D Molecular Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| IKNA | Ikena Oncology, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| BGNE | BeiGene, Ltd. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| RNA | Avidity Biosciences, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| LEGN | Legend Biotech Corporation |
| BCEL | Atreca, Inc. |
| ASND | Ascendis Pharma A/S |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| PCVX | Vaxcyte, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| FIXX | Q32 Bio Inc. |
DNLI Ownership FAQ
Who Owns Denali Therapeutics?
Denali Therapeutics is owned by institutional shareholders (69.91%), insiders (13.61%), and public (16.48%). The largest institutional shareholder of Denali Therapeutics is BAILLIE GIFFORD & CO (9.21% of total shares) and the top mutual fund owner is BNY MELLON VARIABLE INVESTMENT FUND (0.76% of total shares).
Who are the major institutional shareholders of Denali Therapeutics?
Denali Therapeutics's major institutional shareholders are BAILLIE GIFFORD & CO, BLACKROCK INC., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, and CAPITAL RESEARCH GLOBAL INVESTORS. The top five shareholders own together 36.95% of the company's share outstanding.
How many Denali Therapeutics shareholders are there?
As of Jun 2024, there are 161 institutional shareholders of Denali Therapeutics.
What percentage of Denali Therapeutics is owned by BAILLIE GIFFORD & CO?
BAILLIE GIFFORD & CO owns 13.76M shares of Denali Therapeutics, representing 9.21% of the company's total shares outstanding, valued at $319.59M (as of Jun 2024).
What percentage of Denali Therapeutics is owned by BLACKROCK INC?
As of Jun 2024, BLACKROCK INC holds 13.17M shares of Denali Therapeutics (DNLI), compromising 8.82% of the company, valued at $305.91M.
What percentage of Denali Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC is the third largest holder of Denali Therapeutics. The company owns 11.31M of the company's shares outstanding (worth $262.67M).